Literature DB >> 10940196

Current topic: the uteroplacental renin-angiotensin system.

A H Nielsen1, K H Schauser, K Poulsen.   

Abstract

The components of the renin-angiotensin system (RAS) are expressed in the uteroplacental unit. The expression varies between species, probably due to the marked species differences in placental architecture. The conditions for angiotensin (Ang) II formation exist and Ang II receptors are present throughout the human uteroplacental unit, indicating the presence of a functional local RAS. The uteroplacental RAS interacts with other regulatory systems and in this way modulates various aspects of tissue function. It is suggested that the uteroplacental RAS is important for the regeneration of the endometrium after shedding, and for decidualization, implantation and placentation. The RAS participates in the regulation of the uteroplacental blood flow, prostaglandin synthesis and oestradiol secretion. Disturbances of the uteroplacental RAS may lead to dysfunctional bleeding and to reduced uteroplacental blood flow in pregnancies complicated by pre-eclampsia and intrauterine growth retardation. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940196     DOI: 10.1053/plac.2000.0535

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  29 in total

1.  Defining the differential sensitivity to norepinephrine and angiotensin II in the ovine uterine vasculature.

Authors:  Charles R Rosenfeld; Kevin DeSpain; Xiao-tie Liu
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-26       Impact factor: 3.619

Review 2.  The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.

Authors:  Ana Cristina Simões E Silva; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-09-23       Impact factor: 3.714

3.  Luminal ANG II is internalized as a complex with AT1R/AT2R heterodimers to target endoplasmic reticulum in LLC-PK1 cells.

Authors:  Fernanda M Ferrão; Luiza H D Cardoso; Heather A Drummond; Xiao C Li; Jia L Zhuo; Dayene S Gomes; Lucienne S Lara; Adalberto Vieyra; Jennifer Lowe
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-03

Review 4.  The Angiotensin-converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications.

Authors:  Christos Yapijakis; Iphigenia Gintoni; Maria Adamopoulou
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

5.  Differential sensitivity to angiotensin II and norepinephrine in human uterine arteries.

Authors:  Charles R Rosenfeld; Kevin DeSpain; R Ann Word; Xiao-tie Liu
Journal:  J Clin Endocrinol Metab       Date:  2011-10-26       Impact factor: 5.958

6.  Mammary renin-angiotensin system-regulating aminopeptidase activities are modified in rats with breast cancer.

Authors:  Maria del Pilar Carrera; Maria Jesus Ramírez-Expósito; Maria Dolores Mayas; Maria Jesus García; Jose Manuel Martínez-Martos
Journal:  Tumour Biol       Date:  2010-07-21

7.  Vasoreactivity of chorionic plate arteries in response to vasoconstrictors produced by preeclamptic placentas.

Authors:  C Benoit; J Zavecz; Y Wang
Journal:  Placenta       Date:  2006-10-27       Impact factor: 3.481

8.  AT1, AT2, and AT(1-7) receptor expression in the uteroplacental unit of normotensive and hypertensive rats during early and late pregnancy.

Authors:  L M Yamaleyeva; L A A Neves; K Coveleskie; D I Diz; P E Gallagher; K B Brosnihan
Journal:  Placenta       Date:  2013-04-17       Impact factor: 3.481

9.  Contractility of placental vascular smooth muscle cells in response to stimuli produced by the placenta: roles of ACE vs. non-ACE and AT1 vs. AT2 in placental vessel cells.

Authors:  C Benoit; Y Gu; Y Zhang; J S Alexander; Y Wang
Journal:  Placenta       Date:  2008-04-15       Impact factor: 3.481

Review 10.  Pathophysiology of placentation abnormalities in pregnancy-induced hypertension.

Authors:  Mitsuko Furuya; Junji Ishida; Ichiro Aoki; Akiyoshi Fukamizu
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.